Lyell Immunopharma (LYEL) Change in Acquisitions & Divestments (2020 - 2026)

Lyell Immunopharma (LYEL) has 7 years of Change in Acquisitions & Divestments data on file, last reported at $54.6 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments fell 64.54% year-over-year to $54.6 million; the trailing twelve-month figure through Mar 2026 stood at $275.2 million (down 51.97% YoY), and the FY2025 full-year result was $374.7 million, down 31.74% from the prior year.
• Change in Acquisitions & Divestments advanced to $54.6 million in Q1 2026, from $52.9 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $187.1 million in Q2 2023 to a low of $52.9 million in Q4 2025.
• A 5-year average of $121.2 million and a median of $123.7 million in 2024 frame the typical range for Change in Acquisitions & Divestments.
• Across the five-year window, Change in Acquisitions & Divestments surged 78.24% in 2023 and sank 64.54% in 2026, its largest moves.
• Tracing LYEL's Change in Acquisitions & Divestments over 5 years: stood at $110.9 million in 2022, then surged by 40.78% to $156.1 million in 2023, then decreased by 20.77% to $123.7 million in 2024, then slumped by 57.23% to $52.9 million in 2025, then rose by 3.29% to $54.6 million in 2026.
• Business Quant data shows LYEL's Change in Acquisitions & Divestments at $54.6 million in Q1 2026, $52.9 million in Q4 2025, and $74.1 million in Q3 2025.